Zobrazeno 1 - 10
of 10
pro vyhledávání: '"MV Villacañas Palomares"'
Autor:
S Barbadillo, V Martínez Callejo, M Ochagavía Sufrategui, A Garcia-Avello Fernandez-Cueto, MV Villacañas Palomares, VS Carmen Maria, M Martín López, M Valero Domínguez
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3974fdb50ec8dd736ec13cc81fab163d
https://doi.org/10.1136/ejhpharm-2022-eahp.376
https://doi.org/10.1136/ejhpharm-2022-eahp.376
Autor:
CA Alonso Peralta, MV Villacañas Palomares, M. Ochagavía Sufrategui, M Valero Domínguez, CM Valencia Soto, A Garcia De La Paz, V Martinez Callejo, P Del Rio Ortega, S Barbadillo Villanueva, A Garcia-Avello Fernandez-Cueto
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Nivolumab and pembrolizumab are immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1). The introduction of these agents has significantly improved survival outcomes in metastatic non-small cell lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed2fc18f7864e4f0e0e0ab4d88d89695
https://doi.org/10.1136/ejhpharm-2021-eahpconf.100
https://doi.org/10.1136/ejhpharm-2021-eahpconf.100
Autor:
S Barbadillo Villanueva, S Lorenzo Martin, F Uriarte Estefanía, MV Villacañas Palomares, A Colón López de Dicastillo, E Parra Alonso
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Biologic treatment optimisation (BTO) consists of reducing the dose and/or increasing the interval between doses in patients who have maintained their therapeutic goal for at least 6 months. In 2013, our hospital created a B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f239127ea6f7f04738bc46fb5f32091
https://doi.org/10.1136/ejhpharm-2020-eahpconf.419
https://doi.org/10.1136/ejhpharm-2020-eahpconf.419
Autor:
S Lorenzo Martin, A Colón López de Dicastillo, F Uriarte Estefanía, I Gutiérrez Pérez, E Parra Alonso, R Santos del Prado, MV Villacañas Palomares
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Monoclonal antibody PCSK9-inhibitor, evolocumab, is a new drug for the treatment of patients with uncontrolled familial hypercholesterolaemia (FH), uncontrolled stable atherosclerotic cardiovascular disease (ASCVD), mixed dyslipidaemia, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e1558151c2fb544602d95661623b5d0
https://doi.org/10.1136/ejhpharm-2019-eahpconf.462
https://doi.org/10.1136/ejhpharm-2019-eahpconf.462
Autor:
S Guijarro Herrera, J Pastor Hurtado, CM Valencia Soto, JM Ruiz Gonzalez, Toscano Guzmán, E Román Márquez, S Cortes de Miguel, MV Villacañas Palomares
Publikováno v:
Eur J Hosp Pharm
Background In Spain, a therapeutic positioning report (TPR) for sacubitril valsartan indicates its use in adult patients for the treatment of symptomatic chronic heart failure and reduced ejection fraction (left ventricular ejection fraction (LVEF)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda03c7ebf4ca0b8c6947f7e925dcf29
https://doi.org/10.1136/ejhpharm-2018-eahpconf.116
https://doi.org/10.1136/ejhpharm-2018-eahpconf.116
Autor:
MV Calvo Hernández, EM Sáez Fernández, E. Fernandez Dominguez, G Martín García, MV Villacañas Palomares
Publikováno v:
European Journal of Hospital Pharmacy. 23:A133.1-A133
Background Abiraterione is an expensive drug indicated for the treatment of metastasic castration resistant prostate cancer. In order to optimise its use, abiraterone is authorised for use under certain criteria in our hospital. Purpose To analyse co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddcad13e803cfc794c8c3e9aeeaf3e9f
https://doi.org/10.1136/ejhpharm-2016-000875.301
https://doi.org/10.1136/ejhpharm-2016-000875.301
Autor:
Valencia Soto CM; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain carmenmaria.valencia@scsalud.es., Villacañas Palomares MV; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain., Garcia-Avello Fernández-Cueto A; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain., Barbadillo Villanueva S; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain., Martínez Callejo V; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain., Ochagavía Sufrategui M; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain., Muñoz Cacho P; Unidad Docente de Medicina familiar y comunitaria, Idival, Santander, Cantabria, Spain., Valero Domínguez M; Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, Santander, Cantabria, Spain.
Publikováno v:
European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2023 Dec 27; Vol. 31 (1), pp. 40-45. Date of Electronic Publication: 2023 Dec 27.
Autor:
Valencia Soto CM; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Martínez Callejo V; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., García-Avello Fernández-Cueto A; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Villacañas Palomares MV; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Barbadillo Villanueva S; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Ochagavía Sufrategui M; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., López-Brea Piqueras MF; Oncology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Valero Domínguez M; Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Sep; Vol. 29 (6), pp. 1484-1488. Date of Electronic Publication: 2023 May 08.
Autor:
Ochagavía Sufrategui M; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, España. Electronic address: maria.ochagavia@scsalud.es., Gil Lemus MÁ; Servicio de Farmacia Hospitalaria, Hospital Universitario Cruces, Barakaldo, España., Yáñez San Segundo L; Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, España., Amado Diago CA; Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, España., Barbadillo Villanueva S; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, España., Martínez Callejo V; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, España., Villacañas Palomares MV; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, España., Valero Domínguez M; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, España.
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2023 Mar-Apr; Vol. 47 (2), pp. 69-74. Date of Electronic Publication: 2023 Jan 02.
Autor:
Ochagavía Sufrategui M; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: maria.ochagavia@scsalud.es., Gil Lemus MÁ; Servicio de Farmacia Hospitalaria, Hospital Universitario Cruces, Barakaldo, Spain., Yáñez San Segundo L; Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Amado Diago CA; Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Barbadillo Villanueva S; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Martínez Callejo V; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Villacañas Palomares MV; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Valero Domínguez M; Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2023 Mar-Apr; Vol. 47 (2), pp. T69-T74. Date of Electronic Publication: 2023 Jan 23.